Health Care [ 4/12 ] | Biotechnology [ 21/75 ]
NASDAQ | Common Stock
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic.
It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 25 | -2.13 Decreased by -1.02 K% | -2.64 Increased by +19.39% |
| Aug 12, 25 | -2.89 Decreased by -1.51 K% | -0.16 Decreased by -1.67 K% |
| May 13, 25 | -0.18 Increased by +25.45% | -0.17 Decreased by -4.94% |
| Mar 12, 25 | -0.45 Decreased by -122.50% | -0.19 Decreased by -131.17% |
| Nov 7, 24 | -0.19 Decreased by -11.76% | -0.20 Increased by +5.00% |
| Aug 7, 24 | -0.18 Increased by 0.00% | -0.18 Decreased by -0.33% |
| May 6, 24 | -0.24 Decreased by -4.04% | -0.24 Increased by +0.29% |
| Feb 28, 24 | -0.20 Decreased by -400.00% | -0.23 Increased by +13.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 15.00 K Decreased by -55.88% | -38.85 M Increased by +12.87% | Decreased by -258.97 K% Decreased by -97.50% |
| Jun 30, 25 | 8.00 K Decreased by -38.46% | -42.68 M Increased by +6.82% | Decreased by -533.55 K% Decreased by -51.41% |
| Mar 31, 25 | 7.00 K Increased by +133.33% | -52.20 M Increased by +13.96% | Decreased by -745.64 K% Increased by +63.13% |
| Dec 31, 24 | 11.00 K Decreased by -15.38% | -191.94 M Decreased by -262.62% | Decreased by -1.74 M% Decreased by -328.55% |
| Sep 30, 24 | 34.00 K Increased by +36.00% | -44.58 M Increased by +12.33% | Decreased by -131.13 K% Increased by +35.54% |
| Jun 30, 24 | 13.00 K Decreased by -51.85% | -45.81 M Increased by +28.30% | Decreased by -352.38 K% Decreased by -48.91% |
| Mar 31, 24 | 3.00 K Decreased by -95.38% | -60.67 M Increased by +9.40% | Decreased by -2.02 M% Decreased by -1.86 K% |
| Dec 31, 23 | 13.00 K Decreased by -99.97% | -52.93 M Decreased by -530.34% | Decreased by -407.15 K% Decreased by -2.35 M% |